PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION

CLINICAL TRIAL APPLICATION PUBLIC ASSESSEMENT REPORT

PART 1: ADMINSTRATIVE DETAILS

Title of Study and Protocol Version: An open-label, single-arm study to provide continued access to study drug to participants who have completed pediatric clinical studies involving Gilead HIV treatments: GS-US-380-6684 version 1 dated 21 December 2023	**Study Ref: CT278/2024**
Date of receipt of the application: 05 June 2024	
Clinical trial Phase: Phase III/IV	
Study Site(s): University of Zimbabwe Clinical Research Centre, Number 2 Allan Wilson Avenue, Belgravia, Harare, Zimbabwe	
Applicant/Principal Investigator name and address: Professor Hilda Angela Mujuru, University of Zimbabwe Clinical Research Centre, Number 2 Allan Wilson Avenue, Belgravia, Harare, Zimbabwe	
Sponsor name and address: Gilead Sciences Inc, 333 Lakeside Drive Foster City, CA 94404	
Study duration: up to 10 years	
Date of Commencement (Expected or Actual):	
Clinical trial authorisation validity period: 7 January 2025 to 7 April 2030	

PART 2: SUMMARY OF EVALUATION

Study design: An open-label, single-arm phase IV trial. Participants who have completed a parent study and meet all the eligibility criteria will be offered the opportunity to roll over to this study and receive the same regimen as in the parent study

Population:
All participants (male and female participants aged less than 12years up to 18years) who are on parent study medication and have completed a designated Gilead parent study evaluating drugs for HIV treatment are eligible to enroll in this study. The expected number of participants in Zimbabwe is 70 and a total of 350 across the sites.

Study Objectives:

1. Primary objectives: To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; coformulated; Biktarvy®) for participants who completed a Gilead parent study evaluating drugs for HIV treatment
2. Secondary Objectives: To evaluate the safety of the study drug(s) in participants with HIV-1

Eligibility Criteria:

Inclusion Criteria

Participants who meet all of the following inclusion criteria are eligible for participation in this study:

i. Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, GS-US-216-0128, or CO-US-380-5578.
ii. Parent or legal guardian or participant ≥ 18 years of age and able to provide written informed consent. Participants < 18 years of age will provide written assent if they are able per investigator assessment, and if applicable, per their local institutional guidelines and local country regulations.

Exclusion Criteria

i. Participants planning to switch to B/F/TAF on Day 1 cannot have plasma HIV RNA
ii. ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.
iii. Note: participants planning to switch after Day 1 must not have plasma HIV RNA
iv. ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
v. Participants planning to switch to B/F/TAF must not have any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.
vi. For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.
vii. For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.
viii. Ongoing treatment with or prior use of any prohibited medications.

Vulnerable Populations:

Children and adolescents. Only participants for whom informed consent/assent has been provided will be enrolled. Justification for conducting the study is vulnerable population was acceptable.

Informed Consent, Decision-making, Confidentiality & Participant Insurance

Shona and English Informed Consent Forms were provided which were satisfactory. Adequate proof of participant insurance was provided.

Scientific and Technical Issues

The study design was scientifically robust, the justification for the study was acceptable, and follow-up procedures were adequate. All scientific and technical aspects were satisfactory

Other materials, documents and study instruments (Patient recruitment materials, Questionnaires)

Recruitment materials and procedures provided were satisfactory.

Clinical Trials/Study Medicines

i. Emtricitabine/Tenofovir Alafenamide 200mg/25mg tablets (Descovy®) manufactured by Gilead Sciences Inc.
ii. Emtricitabine/Tenofovir Alafenamide 120mg/15mg tablets (Descovy®) manufactured by Gilead Sciences Inc.
iii. Emtricitabine/Tenofovir Alafenamide 60mg/7.5mg tablets (Descovy®) manufactured by Gilead Sciences Inc.
iv. Emtricitabine/Tenofovir Alafenamide 30mg/3.75mg tablets (Descovy®) manufactured by Gilead Sciences Inc.
v. Emtricitabine/Tenofovir Alafenamide 15mg/1.88mg tablets (Descovy®) manufactured by Gilead Sciences Inc.
vi. Cobicistat 30mg tablets (Tybost®) manufactured by Gilead Sciences Inc.
vii. Cobicistat 90mg tablets (Tybost®) manufactured by Gilead Sciences Inc.
viii. Cobicistat 150mg tablets (Tybost®) manufactured by Gilead Sciences Inc.
ix. Bictegravir/Emtricitabine/Tenofovir Alafenamide 50mg/200mg/25 mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc.
x. Bictegravir/Emtricitabine/Tenofovir Alafenamide 30mg/120mg/15mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc.
xi. Bictegravir/Emtricitabine/Tenofovir Alafenamide 15mg/60mg/7.52mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc
xii. Bictegravir/Emtricitabine/Tenofovir Alafenamide 15mg/60mg/7.52mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc
xiii. Bictegravir/Emtricitabine/Tenofovir Alafenamide 7.5mg/30mg/3.76mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc
xiv. Bictegravir/Emtricitabine/Tenofovir Alafenamide 3.76mg/15mg/1.88mg tablets (Biktarvy®) manufactured by Gilead Sciences Inc
xv. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya®) tablets manufactured by Gilead Sciences Inc.
xvi. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 90mg/90mg/120mg/6 mg tablets (Genvoya®): manufactured by Gilead Sciences Inc.
xvii. Darunavir 75mg tablets manufactured by AbbVie Inc.
xviii. Darunavir 400mg tablets manufactured by AbbVie Inc.
xix. Darunavir 600mg tablets and 100mg/ml oral suspension manufactured by AbbVie Inc
xx. Darunavir 100mg/ml oral suspension manufactured by AbbVie Inc
xxi. Atazanavir 300mg capsules (Reyataz®) manufactured by AbbVie Inc.
xxii. Atazanavir 200mg tablets (Reyataz®) manufactured by AbbVie Inc.
xxiii. Atazanavir 50mg oral powder (Reyataz®) manufactured by AbbVie Inc.
xxiv. Lopinavir/Ritonavir 80/20mg/mL oral solution (Kaletra®) manufactured by AbbVie Inc.

The justification for the study products was acceptable.

Summary of review of:

1. Quality
2. Safety
3. Efficacy

Quality, safety, efficacy and risk benefit analysis data was assessed and was satisfactory.

Application Review Process
The application was reviewed under the normal pathway.

Status after review:
The clinical trial application was authorised on the 7th of January 2025

PART 3: OVERALL COMMENTS AND CONCLUSION:

There were no queries raised by the MCAZ Pharmacovigilance and Clinical Trials Committee after the review of the application. The PI was subsequently authorised, with the approval of the Secretary for Health and Child Care, to conduct the trial subject to the contents of the application and the following conditions:

1. Reporting of all serious adverse events to MCAZ;
2. Submission of all amendments to the protocol for approval by MCAZ;
3. Submission of a progress report of the clinical trial by the 31st of January annually;
4. Submission of the final report and copy of any publication of the clinical trial prior to publication of results;
5. In compliance with the current Good Clinical Practices (cGCP) and all other relevant MCAZ guidelines;
6. Submission of the completed indemnity form for conducting clinical trials to the Director-General prior to commencement of the clinical trial;
7. Expiry date of the authorisation is 30 April 2030.

Name of Evaluator S.F Marekera Signature  Date 26/08/2025

Name of 2nd Evaluator T. Nyamandi Signature  Date 26/08/2025